StockWatch
·
Q2 FY-2027 RESULTS · CNCRD

Concord Control H1 FY27 PAT +95% YoY to ₹31.2 Cr, revenue nearly doubles

PAT +94.95% YoY · revenue +95.12% · margins flat

Q2 FY27 resultsCNCRDConcord Control Systems Ltd02 Nov 2026 · 3 min read
Revenue

₹159.11 Cr

+95.12% YoY

PAT (consolidated)

₹31.23 Cr

+94.95% YoY

Net margin

19.38%

-1.4pp YoY

EPS

₹30.08

Concord Control Systems reported consolidated PAT (attributable to owners) of ₹31.23 Cr for H1 FY27 (half year ended 30-Sep-2026), up 94.95% YoY from ₹16.02 Cr in H1 FY26, on consolidated revenue from operations of ₹159.11 Cr, up 95.12% YoY from ₹81.55 Cr. Standalone tells a close but not identical story: standalone PAT of ₹32.86 Cr (+90.27% YoY) is nominally higher in absolute rupees than the consolidated attributable figure — the gap is explained by a ₹1.12 Cr consolidated share-of-loss from two equity-method associates (Progota India Private Ltd, Concord Lab to Market Innovations Private Ltd) plus higher consolidated operating costs, partly offset by a minority-interest credit of ₹0.13 Cr tied to subsidiary Fusion Electronics. Consolidated is the primary basis per our convention; standalone is the secondary read.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹159.11 Cr—+95.1%
Expenses₹117.79 Cr—+91.7%
PAT₹31.23 Cr—+94.95%
Net margin19.38%—-1.4pp
EPS₹30.08—+18.4%

Margins were essentially flat YoY on the primary consolidated basis: net profit margin was 19.38% of total income versus 19.30% a year ago. EBITDA (PBT plus finance cost and depreciation) works out to roughly ₹46.7 Cr, a margin of about 29.3% of revenue — above the 20-25% EBITDA band management guided to at the Q4 FY26 concall (14-May-2026). Finance cost rose to ₹3.18 Cr consolidated from ₹0.54 Cr, and depreciation to ₹2.16 Cr from ₹1.09 Cr, both scaling with the balance sheet (short-term borrowings up to ₹70.97 Cr from ₹39.15 Cr at FY26-end), but neither dented the overall margin.

₹
2,134.192,278.372,422.552,566.732,710.912,43307-3008-2109-1510-0811-02Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹2,433, up 4.8% over the past month of trading.

₹ Cr
011.6123.2334.846.01Q2 FY24rev ₹30 Cr6.8Q4 FY24rev ₹35 Cr8.83Q2 FY25rev ₹50 Cr14.59Q4 FY25rev ₹75 Cr17.27Q2 FY26rev ₹82 Cr31.11Q2 FY27rev ₹159 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 5 consecutive quarters; revenue is at a 6-quarter high.

Beyond the headline

What the summary numbers don't show

No exceptional/extraordinary items in either statement this half or the year-ago half — growth is organic, not one-off driven

What management guided (4 FY-2026 call)
Management is guiding for strong revenue growth, citing a 40-50% CAGR, supported by a record executable order book of INR 697 crores with an 18-24 month execution cycle. The company is targeting a realistic EBITDA margin of 20-25% while managing growth-related working capital needs. Strategically, the focus is on a maj

— This quarter: beat

No formal street/analyst estimates for this quarter could be located — Concord trades at a market cap in the low thousands of crores with limited broker coverage, so vsStreet is marked unknown rather than invented. Against management's own prior guidance (Q4 FY26 concall: 40-50% revenue CAGR off a then-record ₹697 Cr executable order book with an 18-24 month execution cycle, and a 20-25% EBITDA margin target), this print is a clear beat — ~95% YoY revenue growth is well ahead of the guided CAGR range, and the ~29% EBITDA margin sits above the guided band. No separate management press release was available for this filing (board outcome letter and the two Annexure statements plus limited-review reports were the only documents); the only this-quarter corporate markers on record are procedural — the 02-Nov-2026 board meeting that approved these results and a scheduled 29-Oct-2026 post-results concall, which should give the first direct management commentary on this print.

  • W1

    Order-book execution: whether H2 FY27 conversion of the ₹697 Cr order book (18-24 month cycle, per Q4 FY26 concall) sustains the ~95% YoY growth pace toward the guided 40-50% CAGR

  • W2

    Associate-entity losses: consolidated share of loss from Progota India and Concord Lab to Market Innovations was ₹1.12 Cr this half vs ₹1.25 Cr a year ago — watch for a turn to profitability

  • W3

    EBITDA margin durability near ~29% (vs guided 20-25%) as receivables (₹140.76 Cr) and short-term borrowings (₹70.97 Cr) build with growth

Informational and educational content only. Not investment advice.